Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Radiol Imaging Cancer ; 3(5): e210048, 2021 09.
Article in English | MEDLINE | ID: mdl-34559006

ABSTRACT

Purpose To compare disease detection of myeloma using contemporary whole-body (WB) MRI and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate imaging with laboratory estimates of disease burden, including molecular characteristics. Materials and Methods In this observational, prospective study, participants were recruited from November 2015 to March 2018 who had a diagnosis of myeloma, who were planned to undergo chemotherapy and autologous stem cell transplantation, and who underwent baseline WB-MRI and FDG PET/CT (ClinicalTrials.gov identifier NCT02403102). Baseline clinical data, including genetics, were collected. Paired methods were used to compare burden and patterns of disease. Results Sixty participants (mean age, 60 years ± 9 [standard deviation]; 35 men) underwent baseline WB-MRI and FDG PET/CT. WB-MRI showed significantly higher detection for focal lesions at all anatomic sites (except ribs, scapulae, and clavicles) and for diffuse disease at all sites. Two participants presented with two or more focal lesions smaller than 5 mm only at WB-MRI but not FDG PET/CT. Participants with diffuse disease at MRI had higher plasma cell infiltration (percentage of nucleated cells: median, 60% [interquartile range {IQR}, 50%-61%] vs 15% [IQR, 4%-50%]; P = .03) and paraprotein levels (median, 32.0 g/L [IQR, 24.0-48.0 g/L] vs 20.0 g/L [IQR, 12.0-22.6 g/L]; P = .02) compared with those without diffuse disease. All genetically high-risk tumors showed diffuse infiltration at WB-MRI. Conclusion WB-MRI helped detect a higher number of myeloma lesions than FDG PET/CT, and diffuse disease detected at WB-MRI correlated with laboratory measures of disease burden and molecular markers of risk. Keywords: MR-Imaging, Skeletal-Appendicular, Skeletal-Axial, Bone Marrow, Hematologic Diseases, Oncology Clinical trial registration no. NCT02403102. Supplemental material is available for this article. © RSNA, 2021.


Subject(s)
Hematopoietic Stem Cell Transplantation , Multiple Myeloma , Fluorodeoxyglucose F18 , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Multiple Myeloma/diagnostic imaging , Positron Emission Tomography Computed Tomography , Prospective Studies , Transplantation, Autologous
2.
J Med Imaging Radiat Oncol ; 65(7): 888-895, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34219399

ABSTRACT

Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary support primarily used in cardiothoracic and intensive care unit (ICU) settings. The purpose of this review is to familiarise radiologists with the imaging features of ECMO devices, their associated complications and appropriate imaging protocols for contrast-enhanced CT imaging of ECMO patients. This paper will provide a brief introduction to ECMO and the imaging modalities utilised in ECMO patients, followed by a description of the types of ECMO available and cannula positioning. Indications and contraindications for ECMO will be outlined followed by a description of the complications associated with ECMO, which radiologists should recognise. Finally, the imaging protocol and interpretation of contrast-enhanced CT imaging in ECMO patients will be discussed. In the current clinical climate with millions of COVID-19 cases around the world and tens of thousands of critically ill patients, many requiring cardiopulmonary support in intensive care units, the use of ECMO in adults has increased, and thus so has the volume of imaging. Radiologists need to be familiar with the types of ECMO available, the correct positioning of the catheters depending on the type of ECMO being utilised, and the associated complications and imaging artefacts.


Subject(s)
COVID-19 , Extracorporeal Membrane Oxygenation , Adult , Artifacts , Humans , Radiologists , SARS-CoV-2
3.
New Phytol ; 226(2): 523-540, 2020 04.
Article in English | MEDLINE | ID: mdl-31828801

ABSTRACT

Fungal phytopathogens can suppress plant immune mechanisms in order to colonize living host cells. Identifying all the molecular components involved is critical for elaborating a detailed systems-level model of plant infection probing pathogen weaknesses; yet, the hierarchy of molecular events controlling fungal responses to the plant cell is not clear. Here we show how, in the blast fungus Magnaporthe oryzae, terminating rice innate immunity requires a dynamic network of redox-responsive E3 ubiquitin ligases targeting fungal sirtuin 2 (Sir2), an antioxidation regulator required for suppressing the host oxidative burst. Immunoblotting, immunopurification, mass spectrometry and gene functional analyses showed that Sir2 levels responded to oxidative stress via a mechanism involving ubiquitination and three antagonistic E3 ubiquitin ligases: Grr1 and Ptr1 maintained basal Sir2 levels in the absence of oxidative stress; Upl3 facilitated Sir2 accumulation in response to oxidative stress. Grr1 and Upl3 interacted directly with Sir2 in a manner that decreased and scaled with oxidative stress, respectively. Deleting UPL3 depleted Sir2 during growth in rice cells, triggering host immunity and preventing infection. Overexpressing SIR2 in the Δupl3 mutant remediated pathogenicity. Our work reveals how redox-responsive E3 ubiquitin ligases in M. oryzae mediate Sir2 accumulation-dependent antioxidation to modulate plant innate immunity and host susceptibility.


Subject(s)
Magnaporthe , Oryza , Sirtuins , Ascomycota , Fungal Proteins/metabolism , Host-Pathogen Interactions , Immunity, Innate , Magnaporthe/metabolism , Oryza/metabolism , Oxidation-Reduction , Plant Diseases , Plant Immunity , Ubiquitin-Protein Ligases/genetics , Ubiquitin-Protein Ligases/metabolism
4.
J Magn Reson Imaging ; 44(1): 130-7, 2016 07.
Article in English | MEDLINE | ID: mdl-26762608

ABSTRACT

PURPOSE: To evaluate the diagnostic sensitivity of computed diffusion-weighted (DW)-MR imaging for the detection of breast cancer. MATERIALS AND METHODS: Local research ethics approval was obtained. A total of 61 women (median 48 years) underwent dynamic contrast enhanced (DCE)- and DW-MR between January 2011 and March 2012, including 27 with breast cancer on core biopsy and 34 normal cases. Standard ADC maps using all four b values (0, 350, 700, 1150) were used to generate computed DW-MR images at b = 1500 s/mm(2) and b = 2000 s/mm(2) . Four image sets were read sequentially by two readers: acquired b = 1150 s/mm(2) , computed b = 1500 s/mm(2) and b = 2000 s/mm(2) , and DCE-MR at an early time point. Cancer detection was rated using a five-point scale; image quality and background suppression were rated using a four-point scale. The diagnostic sensitivity for breast cancer detection was compared using the McNemar test and inter-reader agreement with a Kappa value. RESULTS: Computed DW-MR resulted in higher overall diagnostic sensitivity with b = 2000 s/mm(2) having a mean diagnostic sensitivity of 76% (range 49.8-93.7%) and b = 1500 s/mm(2) having a mean diagnostic sensitivity of 70.3% (range 32-97.7%) compared with 44.4% (range 25.5-64.7%) for acquired b = 1150 s/mm(2) (both p = 0.0001). Computed DW-MR images produced better image quality and background suppression (mean scores for both readers: 2.55 and 2.9 for b 1500 s/mm(2) ; 2.55 and 3.15 for b 2000 s/mm(2) , respectively) than the acquired b value 1150 s/mm(2) images (mean scores for both readers: 2.4 and 2.45, respectively). CONCLUSION: Computed DW-MR imaging has the potential to improve the diagnostic sensitivity of breast cancer detection compared to acquired DW-MR. J. Magn. Reson. Imaging 2016;44:130-137.


Subject(s)
Algorithms , Breast Neoplasms/diagnostic imaging , Diffusion Magnetic Resonance Imaging/methods , Image Enhancement/methods , Image Interpretation, Computer-Assisted/methods , Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Observer Variation , Reproducibility of Results , Sensitivity and Specificity
5.
Gynecol Oncol ; 133(2): 326-32, 2014 May.
Article in English | MEDLINE | ID: mdl-24582988

ABSTRACT

AIM: The aim of this study is to validate high-resolution endovaginal T2- and diffusion-weighted MRI measurements (tumour size, volume and length of uninvolved cervical canal) against histology in patients undergoing trachelectomy. PATIENTS/INTERVENTIONS: 55 consecutive patients 25-44 years with cervical cancer being considered for trachelectomy were prospectively assessed with endovaginal T2-W and diffusion-weighted MRI. Two independent observers blinded to histology recorded maximum tumour dimension, volume and distance from the superior aspect of the tumour to the internal os. Following trachelectomy, pathologist-outlined tumour sections were photographed with a set scale and similar measurements were recorded. RESULTS: Fifteen of 45 patients subsequently treated with fertility-sparing surgery had residual tumour (median histological volume: 0.28 cm(3), IQR=0.14-1.06 cm(3)). Sensitivity, specificity, positive and negative predictive values for detecting tumour: Observer 1: 86.7%, 80.0%, 68.4%, and 92.3%, respectively; Observer 2: 86.7%, 90.0%, 81.0%, and 93.1%, respectively. Size and volume correlated between observers (r=0.96, 0.84, respectively, p<0.0001). Size correlated between each observer and histology (observer 1 r=0.91, p<0.0001; observer 2 r=0.93, p<0.0001), volume did not (observer 1: r=0.08, p=0.6; observer 2: r=0.21, p=0.16); however, differences between observer measurements and histology were not significant (size p=0.09, volume p=0.15). Differences between MRI and histology estimates of endocervical canal length were not significant (p=0.1 both observers). CONCLUSION: In subcentimetre cervical cancers, endovaginal MRI correlates with pathology and is invaluable in assessing patients for fertility-sparing surgery.


Subject(s)
Carcinoma/pathology , Cervix Uteri/pathology , Hysterectomy/methods , Magnetic Resonance Imaging/methods , Uterine Cervical Neoplasms/pathology , Adult , Carcinoma/diagnosis , Carcinoma/surgery , Cervix Uteri/surgery , Cohort Studies , Diffusion Magnetic Resonance Imaging/methods , Female , Fertility Preservation/methods , Humans , Organ Sparing Treatments/methods , Preoperative Care , Sensitivity and Specificity , Tumor Burden , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/surgery
6.
J Pharmacol Exp Ther ; 346(2): 259-69, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23759509

ABSTRACT

Our previous research showed that enolates formed from 1,3-dicarbonyl compounds, such as 2-acetylcyclopentanone (2-ACP), could provide protection in cell culture models from electrophile- or oxidative stress-induced toxicity. In the present study, we evaluated the protective abilities of 2-ACP in a mouse model of acetaminophen (APAP) hepatotoxicity. Results show that oral APAP overdose (500 mg/kg) was nearly 90% lethal within 72 hours and that the resulting hepatotoxicity was associated with substantial changes in plasma liver enzyme activities, histopathological indices, and markers of hepatocyte oxidative stress. 2-ACP administered intraperitoneally 20 minutes before APAP completely prevented lethality over a 7-day observation period. This effect was dose-dependent (0.80-2.40 mmol/kg) and was correlated with normalization of measured parameters. Nearly complete protection was afforded when 2-ACP was administered 20 minutes post-APAP, but not 60 minutes after intoxication. Although intraperitoneal administration of N-acetylcysteine (NAC) was not effective over a broad dose range (2.40-7.20 mmol/kg), temporal studies indicated that intraperitoneal NAC was hepatoprotective when injected 60 minutes after APAP intoxication. Because of a loss of function in stomach acid, oral administration of 2-ACP was associated with modest APAP protection. In contrast, NAC administered orally provided dose-dependent (0.80-2.40 mmol/kg) protection against APAP hepatotoxicity. In chemico studies and quantum mechanical calculations indicated that 2-ACP acted as a surrogate nucleophilic target for the reactive electrophilic APAP metabolite N-acetyl-p-benzoquinone imine. Our findings suggest that 2-ACP or a derivative might be useful in treating acquired toxicities associated with electrophilic drugs and metabolites or environmental toxicants.


Subject(s)
Acetaminophen/poisoning , Chemical and Drug Induced Liver Injury/prevention & control , Ketones/pharmacology , Acetaminophen/administration & dosage , Acetylcysteine/pharmacology , Acetylcysteine/therapeutic use , Administration, Oral , Animals , Biomarkers/blood , Chemical and Drug Induced Liver Injury/metabolism , Chemical and Drug Induced Liver Injury/pathology , Hepatocytes/drug effects , Hepatocytes/metabolism , Injections, Intraperitoneal , Ketones/therapeutic use , Liver/drug effects , Liver/metabolism , Liver/pathology , Male , Mice , Mice, Inbred C57BL , Oxidative Stress , Quantum Theory
7.
Curr Opin Oncol ; 23(5): 519-25, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21602677

ABSTRACT

PURPOSE OF REVIEW: There has been considerable progress in the imaging of cervical cancer over the last 5 years. In countries with access to cross-sectional imaging resources, technical advances have enabled a range of imaging techniques to become increasingly employed and established in the detection, staging and treatment planning of cervical cancer and for identifying disease recurrence. This review highlights these developments and summarizes recent significant articles. RECENT FINDINGS: Functional imaging techniques provide information on tumour biology by probing characteristics of tumour vascularity, cellularity and metabolism which critically contribute to decision making and stratification for management options. Particularly, functional MRI techniques have improved accuracy of disease staging and detection of recurrence. PET-computed tomography is useful in lymph node staging and targeted radiotracers are increasingly exploited as potential biomarkers of treatment response. SUMMARY: Improvements in hardware, software and contrast agents are revolutionizing the role of imaging in cervical cancer. Once standardized and validated, the techniques should enable individualized patient treatment and optimization of outcome.


Subject(s)
Magnetic Resonance Imaging/trends , Multimodal Imaging/trends , Positron-Emission Tomography , Tomography, X-Ray Computed , Uterine Cervical Neoplasms/diagnosis , Antineoplastic Protocols , Female , Humans , Magnetic Resonance Imaging/methods , Multimodal Imaging/methods , Neoplasm Staging/methods , Prognosis , Uterine Cervical Neoplasms/classification , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/therapy
9.
Pediatr Dev Pathol ; 13(6): 471-5, 2010.
Article in English | MEDLINE | ID: mdl-20331366

ABSTRACT

Intestinal spirochetosis (IS) is an unusual infection in children, one with no standard therapeutic options. This article reports the findings on 5 new cases in conjunction with a 20-year review of the pediatric literature. The diagnosis of IS in children requires a high degree of suspicion by the physician, as many cases present with abdominal pain, chronic diarrhea, and/or hematochezia associated with a normal endoscopic examination. Silver stains (Dieterle or Whartin-Starry) are the preferred confirmatory stains on tissue sections. Giemsa (Diff-Quik) and periodic acid-Schiff stains may also be of value. Current literature favors the use of metronidazole in adult patients with IS, yet little information is available regarding treatment options in pediatric cases. This review indicates that a macrolide antibiotic with or without metronidazole may represent the best therapeutic choice for children. Further investigations are needed to determine the correlation between IS and coexisting gastrointestinal diseases and/or immunodeficiencies.


Subject(s)
Intestinal Diseases/microbiology , Spirochaetales Infections/microbiology , Spirochaetales/isolation & purification , Adolescent , Anti-Bacterial Agents/therapeutic use , Child , Female , Humans , Intestinal Diseases/drug therapy , Intestinal Diseases/pathology , Macrolides/therapeutic use , Male , Metronidazole/therapeutic use , Spirochaetales Infections/drug therapy , Spirochaetales Infections/pathology , Treatment Outcome
10.
J Rheumatol ; 35(6): 1083-91, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18464303

ABSTRACT

OBJECTIVE: Emerging evidence suggests that clinically important antiinflammatory effects of HMG-CoA reductase inhibition may extend beyond cardiovascular disease to other inflammatory disorders, such as rheumatoid arthritis (RA). Protective bone-specific anabolic and antiresorptive effects of HMG-CoA reductase inhibitors have also been evaluated in normal and osteoporotic bone. The specific effect of statins on inflammation-induced bone loss has not previously been a focus of evaluation. We investigated whether simvastatin, a potent HMG-CoA reductase inhibitor, alters bone turnover in an animal model of RA, thus preventing periarticular bone loss. METHODS: Hydrolyzed simvastatin (20 mg/kg/day) was administered subcutaneously to female Lewis rats 4 days before or 8 days after induction of arthritis by intraperitoneal injection of streptococcal cell wall or vehicle. Effects of simvastatin (vs vehicle) on periarticular bone, assessed by bone mineral density (BMD), biochemical markers of bone turnover, and joint histology, were determined. Effects on joint swelling were assessed clinically and histologically. RESULTS: Simvastatin prevented early and late joint inflammation in association with a decrease in articular macrophage influx. Simvastatin suppressed the periarticular bone destruction occurring late in the course of disease, preserving periarticular BMD and preventing increases in periarticular osteoclasts and serum pyridinoline levels in arthritic animals, while having no effect on these measures in normal animals. Osteocalcin levels, which were decreased in arthritic animals, were unaltered by statin treatment. CONCLUSION: Our results suggest that inhibition of HMG-CoA reductase may be therapeutically useful in preserving periarticular bone in RA joints via suppression of inflammation-induced bone resorption.


Subject(s)
Arthritis, Experimental/complications , Bone Resorption/complications , Bone Resorption/prevention & control , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Simvastatin/therapeutic use , Animals , Arthritis, Experimental/drug therapy , Bone Density , Bone Resorption/pathology , Female , Rats , Rats, Inbred Lew
11.
Am J Physiol Regul Integr Comp Physiol ; 284(4): R1021-30, 2003 Apr.
Article in English | MEDLINE | ID: mdl-12456385

ABSTRACT

Parathyroid hormone-related protein (PTHrP) is a multifunctional peptide that enhances blood flow in non-central nervous system (CNS) vascular beds by causing vasodilation. PTHrP expression is induced in non-CNS organs in response to ischemia. Experiments were therefore undertaken to determine whether PTHrP can be induced in brain in response to ischemic injury and whether PTHrP can act locally as a vasodilator in the cerebral vasculature, an effect that could be neuroprotective in the setting of stroke. PTHrP expression was examined by Northern analysis and immunohistochemical staining in male Sprague-Dawley rats subjected to permanent middle cerebral artery occlusion (MCAO). Vasodilatory effects of superfused PTHrP(1-34) on pial arterioles were determined by intravital fluorescence microscopy. Effects of PTHrP(1-34) peptide administration on MCAO infarction size reduction were assessed. PTHrP expression was induced in the ischemic hemisphere as early as 4 h after MCAO and remained elevated for up to 24 h. Increased immunoreactive PTHrP at sites of ischemic tissue injury was located in the cerebral microvessels. Superfusion with PTHrP(1-34) peptide for up to 25 min increased pial arteriolar diameter by 30% in normal animals. In animals with permanent MCAO, PTHrP(1-34) peptide treatment significantly decreased cortical infarct size (-47%). In summary, PTHrP expression increases at sites of ischemic brain injury in the cerebrovasculature. This local increase in PTHrP could be an adaptive response that enhances blood flow to the ischemic brain, thus limiting cell injury.


Subject(s)
Cerebral Infarction/pathology , Gene Expression Regulation , Neuroprotective Agents/metabolism , Peptide Hormones/metabolism , Animals , Arterioles/drug effects , Brain/blood supply , Brain/pathology , Brain/surgery , Cytokines/genetics , Male , Middle Cerebral Artery/physiology , Middle Cerebral Artery/surgery , Neuroprotective Agents/pharmacology , Parathyroid Hormone-Related Protein , Peptide Hormones/genetics , Peptide Hormones/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Time Factors , Vasodilation/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...